MITF

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Retrieved on: 
Wednesday, January 10, 2024
Vitiligo, Patient, Therapy, LEF1, MITF, Factorization of polynomials, Melanocyte, Skin, Safety, Protein, Inflammation, Biomarker, SOX10, BET, Pharmacokinetics, Week

The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.

Key Points: 
  • The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.
  • Positive clinical data from the Phase 1b trial were announced in October 2023.
  • One lesion, selected for treatment with VYN201, had skin tissue biopsies taken prior to first application of VYN201 and after 8 weeks of treatment.
  • “We are encouraged by these new biomarker data from the Phase 1b trial for VYN201, building on our recently announced positive clinical results,” said David Domzalski, President and CEO of VYNE.